<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01196091</url>
  </required_header>
  <id_info>
    <org_study_id>13656</org_study_id>
    <secondary_id>H9B-MC -BCDS</secondary_id>
    <nct_id>NCT01196091</nct_id>
  </id_info>
  <brief_title>A Study of LY2127399 in Participants With Systemic Lupus Erythematosus</brief_title>
  <official_title>A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this SLE study is to evaluate the efficacy, safety and tolerability of two
      different doses of LY2127399 administered in participants with active SLE.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Achieving an SLE Responder Index Response at Week 52</measure>
    <time_frame>52 weeks</time_frame>
    <description>Percentage of participants with a ≥ 5 point reduction from baseline in SELENA SLEDAI score, and no worsening (increase of &lt; 0.30 points from baseline) in PGA, and no new BILAG A organ domain score or 2 new BILAG B organ domain scores compared with baseline.
SELENA SLEDAI is calculated from 24 individual descriptors across 9 organ systems; 0 indicates inactive disease and the maximum theoretical score is 105; scores &gt; 20 are rare. PGA is a visual analog scale scored from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe). BILAG uses a single score for each of the 9 organ domains; range is from severe (A) to no disease (E). Participants who were unable to comply with allowed concomitant medications requirements were considered non-responders, as were participants who dropped out or were missing Week 52 data.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage Participants Able to Decrease Dose of Prednisone or Equivalent With No Increase in Disease Activity at Week 52</measure>
    <time_frame>52 weeks</time_frame>
    <description>A participant achieves corticosteroid sparing effects (quiescent disease) if they have met the following criteria during Weeks 24 through 52; able to decrease their dose of prednisone or equivalent to 7.5 mg/day or less, have quiescent disease (BILAG C score or better in all nine systems), and no BILAG A or B flares in the previous three months, without an increase in either antimalarials or immunosuppressants on or prior to the visit. Only participants receiving a prednisone or equivalent dose of more than 7.5 mg/day at baseline are included.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 52 Weeks in Anti-double Stranded Deoxyribonucleic Acid (Anti-dsDNA) Level</measure>
    <time_frame>Baseline, 52 weeks</time_frame>
    <description>Anti-double stranded deoxyribonucleic acid (anti-dsDNA) is a lab analyte used to assist in the diagnosis of SLE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 52 Week Endpoint in Systemic Lupus Erythematosus Disease Activity Index (SLEDAI2K) Score</measure>
    <time_frame>Baseline, 52 weeks</time_frame>
    <description>SLE Disease Activity Index 2000 (SLEDAI-2K) score is a weighted, cumulative index of lupus disease activity. SLEDAI-2K is calculated from 24 individual descriptors across 9 organ systems; 0 indicates inactive disease and the maximum theoretical score is 105.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Severe SLE Flare (SFI)</measure>
    <time_frame>Baseline through 52 weeks</time_frame>
    <description>The SFI uses the SELENA-SLEDAI disease activity index score, disease activity scenarios, treatment changes, and PGA to define mild/moderate and severe flares. The index takes into account the absolute change in total scores, new or worsening symptoms, and increases in corticosteroid use or hospitalization due to the disease activity.
Time to first severe SLE flare (SFI) (in days) is calculated as: (Start date of first severe SLE flare (SFI) - Date of randomization + 1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With No Worsening in Physician Global Assessment (PGA) Score at 52 Weeks</measure>
    <time_frame>52 weeks</time_frame>
    <description>Physician's Global Assessment (PGA) is a single-item clinician rated assessment of the patient's current level of disease activity measured on a continuous 100 millimeter (mm) visual analytic scale with benchmarks of 0, 1, 2, and 3 from left to right corresponding to no, mild, moderate, and severe SLE disease activity. Scores are presented from 0 to 100. No worsening is defined as increase of ≥0.3 points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 52 Week Endpoint in Brief Fatigue Inventory (BFI) Scores</measure>
    <time_frame>Baseline, 52 weeks</time_frame>
    <description>A participants-reported scale that measures the severity of fatigue based on the worst fatigue experienced during the past 24-hours. The severity scores ranged from 0 (no fatigue) to 10 (fatigue as severe as you can imagine).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 52 Week Endpoint Lupus Quality of Life (LupusQoL) Domain Scores</measure>
    <time_frame>Baseline, 52 weeks</time_frame>
    <description>The LupusQoL is a disease-specific, 34-item, self-report questionnaire designed to measure the health-related quality of life (HRQoL) of participants with SLE within 8 domains.Responses are based on a 5-point Likert scale where 0 (all of the time) to 4 (never). A LupusQoL score for each domain is reported on a 0 to 100 scale, with greater values indicating better HRQoL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First New British Isles Lupus Assessment Group (BILAG A) or 2 New BILAG B SLE Flares</measure>
    <time_frame>Baseline through 52 weeks</time_frame>
    <description>The British Isles Lupus Assessment Group (BILAG) instrument assesses global disease activity across 9 organ system domains. BILAG flare is assessed for each of the 9 organ domains using BILAG2004 index flare rules; A is a severe flare and B is a moderate flare.
Time to first BILAG A or two BILAG B flares (in days) is calculated as: (Start date of first BILAG A or two BILAG B flares - Date of randomization + 1). The two BILAG B flares must occur in different domains at the same visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 52 Week Endpoint in PGA</measure>
    <time_frame>Baseline, 52 weeks</time_frame>
    <description>Physician's Global Assessment (PGA) is a single-item clinician rated assessment of the patient's current level of disease activity measured on a continuous 100-mm visual analytic scale with benchmarks of 0, 1, 2, and 3 from left to right corresponding to no, mild, moderate, and severe SLE disease activity. Scores range from 0, being worst possible to 100 being very active or best possible.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With an Increase in Corticosteroids Dose at 52 Weeks</measure>
    <time_frame>52 weeks</time_frame>
    <description>An increase in corticosteroids at a visit was defined as a change from baseline greater than 2.5 mg/day in dose or prednisone or equivalent using average daily dose of corticosteroids taken since the previous scheduled visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 52 Weeks Endpoint in SELENA-SLEDAI Disease Activity Score</measure>
    <time_frame>Baseline, 52 weeks</time_frame>
    <description>Safety of Estrogens in Lupus Erythematosus National Assessment - SLE Disease Activity Index (SELENA-SLEDAI) score is a weighted, cumulative index of lupus disease activity. SELENA-SLEDAI is calculated from 24 individual descriptors across 9 organ systems; 0 indicates inactive disease and the maximum theoretical score is 105.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving a Response as Measured by Modified SRI With No BILAG A or No More Than 1 BILAG B Organ Domain Flares at 52 Weeks</measure>
    <time_frame>52 weeks</time_frame>
    <description>Percentage of participants with a ≥ 5 point reduction from baseline in SELENA SLEDAI score, and no worsening (increase of &lt; 0.30 points from baseline) in PGA, and no new BILAG A or no more than 1 new BILAG B organ domain flare compared with baseline. (Primary outcome modified to use BILAG flare instead of BILAG disease score)
SELENA SLEDAI is calculated from 24 individual descriptors across 9 organ systems; 0 indicates inactive disease and the maximum theoretical score is 105. PGA is a visual analog scale scored from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe). BILAG flare is assessed for each of the 9 organ domains; A is a severe flare and B is a moderate flare. Patients who were unable to comply with allowed concomitant medications requirements were considered non-responders, as were participants who dropped out or were missing Week 52 data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With No New BILAG A and No More Than One New BILAG B Disease Activity Scores Compared to Baseline</measure>
    <time_frame>Baseline through 52 weeks</time_frame>
    <description>The BILAG2004 index is a validated global disease activity index designed on the basis of the physician's ITT, focusing on changes in disease manifestations (new, improved, worsening, etc) occurring in the last 4 weeks compared with the previous 4 weeks.
The instrument assesses 97 clinical signs, symptoms, and laboratory parameters across 9 organ system domains: constitutional, mucocutaneous, neuropsychiatric, musculoskeletal, cardiorespiratory, gastrointestinal, opthalmic, renal and hematology.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1164</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <condition>Connective Tissue Disease</condition>
  <condition>Autoimmune Disease</condition>
  <arm_group>
    <arm_group_label>LY2127399 every 2 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered SC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY2127399 every 4 wks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During the Treatment Period, for blinding purposes, patients will alternate injections of LY2127399 and injections of placebo every 2 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Administered SC</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2127399</intervention_name>
    <description>120 mg administered via subcutaneous (SC) injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug.</description>
    <arm_group_label>LY2127399 every 2 weeks</arm_group_label>
    <arm_group_label>LY2127399 every 4 wks</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo every 2 weeks</intervention_name>
    <description>Administered via subcutaneous injection for 52 weeks. A matching loading dose of corticosteroids, NSAIDs, antimalarials, or immunosuppressants will also be administered at the first dose</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo every 4 weeks</intervention_name>
    <description>Administered via subcutaneous injection for 52 weeks.</description>
    <arm_group_label>LY2127399 every 4 wks</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard of Care</intervention_name>
    <arm_group_label>LY2127399 every 2 weeks</arm_group_label>
    <arm_group_label>LY2127399 every 4 wks</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Non-steroidal anti-inflammatory drug</other_name>
    <other_name>Corticosteroids</other_name>
    <other_name>Antimalarials (used for SLE)</other_name>
    <other_name>Immunosuppressants</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of SLE by American College of Rheumatology (ACR) criteria

          -  Have positive antinuclear antibodies (ANA)

          -  Agree not to become pregnant throughout the course of the trial

          -  Have a screening SELENA-SLEDAI score ≥6. (The participant must be actively exhibiting
             all the symptoms scored on the screening SELENA-SLEDAI on the day of screening.)

        Exclusion Criteria:

          -  Have active severe Lupus kidney disease

          -  Have active Central Nervous System or peripheral neurologic disease

          -  Have received intravenous immunoglobulin (IVIg) within 180 days of randomization

          -  Have active or recent infection within 30 days of screening

          -  Have had a serious infection within 90 days of randomization

          -  Have evidence or test positive for Hepatitis B

          -  Have Hepatitis C

          -  Are human immunodeficiency virus (HIV) positive

          -  Have evidence of active or latent tuberculosis (TB)

          -  Presence of significant laboratory abnormalities at screening

          -  Have had a malignancy in the past 5 years, except for cervical carcinoma in-situ or
             basal cell or squamous epithelial skin cell that were completely resected with no
             reoccurrence in the 3 yrs prior to randomization

          -  Have received greater than 40 mgs of prednisone or equivalent in the past 30 days

          -  Have changed your dose of antimalarial drug in the past 30 days

          -  Have changed your dose of immunosuppressive drug in the past 90 days

          -  Have previously received rituximab
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9AM - 5PM Eastern time (UTC/GMT -5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Paradise Valley</city>
        <state>Arizona</state>
        <zip>85253</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Peoria</city>
        <state>Arizona</state>
        <zip>85381</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lakewood</city>
        <state>California</state>
        <zip>90712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95825</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>San Leandro</city>
        <state>California</state>
        <zip>94578</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Upland</city>
        <state>California</state>
        <zip>91786</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Danbury</city>
        <state>Connecticut</state>
        <zip>06810</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Farmington</city>
        <state>Connecticut</state>
        <zip>06030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Norwich</city>
        <state>Connecticut</state>
        <zip>06360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Trumbull</city>
        <state>Connecticut</state>
        <zip>06611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Doral</city>
        <state>Florida</state>
        <zip>33166</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33334</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lake Mary</city>
        <state>Florida</state>
        <zip>32746</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Orange Park</city>
        <state>Florida</state>
        <zip>32073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Palm Harbor</city>
        <state>Florida</state>
        <zip>34684</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tamarac</city>
        <state>Florida</state>
        <zip>33321</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61636</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Muncie</city>
        <state>Indiana</state>
        <zip>47304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bowling Green</city>
        <state>Kentucky</state>
        <zip>42101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hagerstown</city>
        <state>Maryland</state>
        <zip>21742</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Wheaton</city>
        <state>Maryland</state>
        <zip>20902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49546</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Eagan</city>
        <state>Minnesota</state>
        <zip>55121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Florissant</city>
        <state>Missouri</state>
        <zip>63031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68516</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Clifton</city>
        <state>New Jersey</state>
        <zip>07012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Teaneck</city>
        <state>New Jersey</state>
        <zip>07666</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Toms River</city>
        <state>New Jersey</state>
        <zip>08755</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10457</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Endwell</city>
        <state>New York</state>
        <zip>13760</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10019</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hickory</city>
        <state>North Carolina</state>
        <zip>28602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Middleburg Heights</city>
        <state>Ohio</state>
        <zip>44130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Edmond</city>
        <state>Oklahoma</state>
        <zip>73013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Willow Grove</city>
        <state>Pennsylvania</state>
        <zip>19090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>North Charleston</city>
        <state>South Carolina</state>
        <zip>29406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Crossville</city>
        <state>Tennessee</state>
        <zip>38555</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hixon</city>
        <state>Tennessee</state>
        <zip>37343</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Allen</city>
        <state>Texas</state>
        <zip>75013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Irving</city>
        <state>Texas</state>
        <zip>75061</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Mesquite</city>
        <state>Texas</state>
        <zip>75150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77478</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Waco</city>
        <state>Texas</state>
        <zip>76708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Chesapeake</city>
        <state>Virginia</state>
        <zip>23320</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Danville</city>
        <state>Virginia</state>
        <zip>24541</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Williamsburg</city>
        <state>Virginia</state>
        <zip>23185</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1417EYG</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Caba</city>
        <zip>C1181ACH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Córdoba</city>
        <zip>X5016KEH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Rosario</city>
        <zip>S2000PBJ</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>San Juan</city>
        <zip>5400</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tucuman</city>
        <zip>4000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Vienna</city>
        <zip>A1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Brest</city>
        <zip>224027</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Grodno</city>
        <zip>230017</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Minsk</city>
        <zip>220116</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Plovdiv</city>
        <zip>4002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sofia</city>
        <zip>1612</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Stara Zagora</city>
        <zip>6003</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Varna</city>
        <zip>9010</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <zip>V1Y3G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Markham</city>
        <state>Ontario</state>
        <zip>L3P1A8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>L3Y3R7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Osorno</city>
        <zip>5290000</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Santiago</city>
        <zip>7500000</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Valdivia</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bucaramanga</city>
        <zip>681001</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cali</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Chia</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Medellín</city>
        <zip>574</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Osijek</city>
        <zip>31000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Al Minya</city>
        <zip>61111</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Alexandria</city>
        <zip>21131</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cairo</city>
        <zip>941400</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bad Nauheim</city>
        <zip>61231</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Baden-Baden</city>
        <zip>76530</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Berlin</city>
        <zip>14059</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hildesheim</city>
        <zip>31134</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Jena</city>
        <zip>07747</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Zerbst</city>
        <zip>39261</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Guatemala</city>
        <zip>1010</zip>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Brescia</city>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Palermo</city>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Scafati</city>
        <zip>84018</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Torino</city>
        <zip>10128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Aichi</city>
        <zip>4600001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Chiba</city>
        <zip>284-0003</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Fukuoka</city>
        <zip>807-8556</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hokkaido</city>
        <zip>060-8648</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Japan</city>
        <zip>852-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Miyagi</city>
        <zip>980-8574</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nagasaki</city>
        <zip>856-8562</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Osaka</city>
        <zip>530-8480</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tokyo</city>
        <zip>101-0062</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bucheon</city>
        <zip>420-717</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Daegu</city>
        <zip>700-712</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Daejeon</city>
        <zip>301-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Gwangju</city>
        <zip>501-757</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Incheon</city>
        <zip>405-760</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Jeonju-Si</city>
        <zip>561712</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Seoul</city>
        <zip>143-729</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Suwon</city>
        <zip>443-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bitola</city>
        <zip>7000</zip>
        <country>Macedonia, The Former Yugoslav Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Skopje</city>
        <zip>1000</zip>
        <country>Macedonia, The Former Yugoslav Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Stip</city>
        <zip>2000</zip>
        <country>Macedonia, The Former Yugoslav Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Arequipa</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lima</city>
        <zip>L41</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lince</city>
        <zip>Lima14</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Piura</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Angeles City</city>
        <zip>2009</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cebu</city>
        <zip>6000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Davao City</city>
        <zip>8000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ermita</city>
        <zip>1000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Espana</city>
        <zip>1008</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Iloilo City</city>
        <zip>5000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Manila</city>
        <zip>1007</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Paranaque</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Quezon City</city>
        <zip>1102</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>?Ód?</city>
        <zip>94-017</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bytom</city>
        <zip>41-902</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Poznan</city>
        <zip>61-397</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sosnowiec</city>
        <zip>41-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Warsaw</city>
        <zip>02-507</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Wroc?Aw</city>
        <zip>50-368</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>San Juan</city>
        <zip>00918</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Santurce</city>
        <zip>00909</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Singapore</city>
        <zip>258499</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Chiang Mai</city>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Donetsk</city>
        <zip>83001</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <zip>76008</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kharkiv</city>
        <zip>61029</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kryvyi Rih</city>
        <zip>50056</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kyiv</city>
        <zip>1601</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lviv</city>
        <zip>79011</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Odesa</city>
        <zip>65025</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Simferopol</city>
        <zip>95017</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ternopil</city>
        <zip>46002</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Uzhorod</city>
        <zip>88018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Vinnytsya</city>
        <zip>21018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Zaporizhzhia</city>
        <zip>69600</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Zhytomyr</city>
        <zip>10002</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Austria</country>
    <country>Belarus</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Croatia</country>
    <country>Egypt</country>
    <country>Germany</country>
    <country>Guatemala</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Macedonia, The Former Yugoslav Republic of</country>
    <country>Peru</country>
    <country>Philippines</country>
    <country>Poland</country>
    <country>Puerto Rico</country>
    <country>Singapore</country>
    <country>Thailand</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Turkey</country>
  </removed_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>September 3, 2010</study_first_submitted>
  <study_first_submitted_qc>September 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2010</study_first_posted>
  <results_first_submitted>March 24, 2018</results_first_submitted>
  <results_first_submitted_qc>June 11, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">June 12, 2018</results_first_posted>
  <disposition_first_submitted>September 29, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>September 29, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 8, 2014</disposition_first_posted>
  <last_update_submitted>June 11, 2018</last_update_submitted>
  <last_update_submitted_qc>June 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lupus</keyword>
  <keyword>SLE</keyword>
  <keyword>Systemic Lupus Erythematosis</keyword>
  <keyword>autoimmune disease</keyword>
  <keyword>LY2127399</keyword>
  <keyword>Immune system disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
    <mesh_term>Connective Tissue Diseases</mesh_term>
    <mesh_term>Autoimmune Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antimalarials</mesh_term>
    <mesh_term>Anti-Inflammatory Agents, Non-Steroidal</mesh_term>
    <mesh_term>Anti-Inflammatory Agents</mesh_term>
    <mesh_term>Immunosuppressive Agents</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Intent to Treat population (ITT) is all randomized participants who received at least 1 dose of study drug, excluding two sites' participants due to good clinical practice (GCP) issues.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>LY2127399 Every 2 Weeks</title>
          <description>LY2127399: 120 mg administered via subcutaneous injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug.</description>
        </group>
        <group group_id="P2">
          <title>LY2127399 Every 4 Wks</title>
          <description>During the Treatment Period, for blinding purposes, patients will alternate injections of LY2127399 and injections of placebo every 2 weeks.
LY2127399: 120 mg administered via subcutaneous injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug.
Placebo every 4 weeks: Administered via subcutaneous injection for 52 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo every 2 weeks: Administered via subcutaneous injection for 52 weeks. A matching loading dose will also be administered at the first dose</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="387"/>
                <participants group_id="P2" count="389"/>
                <participants group_id="P3" count="388"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least 1 Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="386"/>
                <participants group_id="P2" count="389"/>
                <participants group_id="P3" count="387"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>ITT-Received Drug and Excluded Sites</title>
              <participants_list>
                <participants group_id="P1" count="381"/>
                <participants group_id="P2" count="378"/>
                <participants group_id="P3" count="379"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Follow-Up</title>
              <participants_list>
                <participants group_id="P1" count="103"/>
                <participants group_id="P2" count="105"/>
                <participants group_id="P3" count="128"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="299"/>
                <participants group_id="P2" count="291"/>
                <participants group_id="P3" count="284"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="88"/>
                <participants group_id="P2" count="98"/>
                <participants group_id="P3" count="104"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="27"/>
                <participants group_id="P3" count="26"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Entry Criteria Not Met</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Parent/Caregiver Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="22"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor Decision</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Excluded Site</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomized, No Study Drug Received</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent to Treat population (ITT) all randomized participants who received at least 1 dose of study drug: except those at Sites 301 and 383, which were excluded due to suspected good clinical practice (GCP) issues.</population>
      <group_list>
        <group group_id="B1">
          <title>LY2127399 Every 2 Weeks</title>
          <description>LY2127399: 120 mg administered via subcutaneous injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug.</description>
        </group>
        <group group_id="B2">
          <title>LY2127399 Every 4 Wks</title>
          <description>During the Treatment Period, for blinding purposes, patients will alternate injections of LY2127399 and injections of placebo every 2 weeks.
LY2127399: 120 mg administered via subcutaneous injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug.
Placebo every 4 weeks: Administered via subcutaneous injection for 52 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo every 2 weeks: Administered via subcutaneous injection for 52 weeks. A matching loading dose will also be administered at the first dose</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="381"/>
            <count group_id="B2" value="378"/>
            <count group_id="B3" value="379"/>
            <count group_id="B4" value="1138"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.8" spread="12.51"/>
                    <measurement group_id="B2" value="40.2" spread="11.21"/>
                    <measurement group_id="B3" value="39.1" spread="11.69"/>
                    <measurement group_id="B4" value="39.7" spread="11.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="354"/>
                    <measurement group_id="B2" value="352"/>
                    <measurement group_id="B3" value="360"/>
                    <measurement group_id="B4" value="1066"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="119"/>
                    <measurement group_id="B2" value="116"/>
                    <measurement group_id="B3" value="122"/>
                    <measurement group_id="B4" value="357"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="233"/>
                    <measurement group_id="B2" value="225"/>
                    <measurement group_id="B3" value="229"/>
                    <measurement group_id="B4" value="687"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="67"/>
                    <measurement group_id="B4" value="187"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="66"/>
                    <measurement group_id="B4" value="195"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="39"/>
                    <measurement group_id="B4" value="120"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="204"/>
                    <measurement group_id="B2" value="218"/>
                    <measurement group_id="B3" value="205"/>
                    <measurement group_id="B4" value="627"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Colombia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Argentina</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Puerto Rico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Singapore</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="128"/>
                    <measurement group_id="B2" value="133"/>
                    <measurement group_id="B3" value="116"/>
                    <measurement group_id="B4" value="377"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Philippines</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Egypt</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ukraine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thailand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belarus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Macedonia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Guatemala</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Korea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bulgaria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peru</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Croatia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Anti-dsDNA Antibody Level</title>
          <units>International Units/Milliliter (IU/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="107.2" spread="113.50"/>
                    <measurement group_id="B2" value="110.4" spread="111.58"/>
                    <measurement group_id="B3" value="107.1" spread="112.40"/>
                    <measurement group_id="B4" value="108.2" spread="112.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA-SLEDAI) Score</title>
          <description>Safety of Estrogens in Lupus Erythematosus National Assessment - SLE Disease Activity Index (SELENA-SLEDAI) score is a weighted, cumulative index of lupus disease activity. SELENA-SLEDAI is calculated from 24 individual descriptors across 9 organ systems; 0 indicates inactive disease and the maximum theoretical score is 105.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.2" spread="3.5"/>
                    <measurement group_id="B2" value="10.4" spread="3.6"/>
                    <measurement group_id="B3" value="10.7" spread="3.9"/>
                    <measurement group_id="B4" value="10.4" spread="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Physician's Global Assessment (PGA) Score</title>
          <description>PGA is a single-item clinician rated assessment of the participant's current level of disease activity measured on a continuous 0 to 100-millimeter (mm) visual analytic scale with benchmarks of 0, 1, 2, and 3 from left to right corresponding to no, mild, moderate, and severe SLE disease activity. Scores range from 0, being worst possible to 100 being very active or best possible.</description>
          <units>millimeters (mm)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.3" spread="15.7"/>
                    <measurement group_id="B2" value="46.1" spread="16.2"/>
                    <measurement group_id="B3" value="47.1" spread="16.10"/>
                    <measurement group_id="B4" value="46.5" spread="16.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time of Onset of Lupus</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.5" spread="7.4"/>
                    <measurement group_id="B2" value="8.1" spread="7.9"/>
                    <measurement group_id="B3" value="6.4" spread="6.8"/>
                    <measurement group_id="B4" value="7.3" spread="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>At Least One BILAG A or Two BILAG B Disease Activity Scores</title>
          <description>The British Isles Lupus Assessment Group (BILAG) instrument assesses global disease activity across 9 organ system domains. BILAG flare is assessed for each of the 9 organ domains using BILAG2004 index flare rules; A is a severe flare and B is a moderate flare.
The sum of participants in all Categories for the Measure does not equal the Overall Number of Baseline Participants in the Arm/Group because not all participants will have at least one BILAG A or Two BILAG B Disease Activity scores.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="360"/>
                    <measurement group_id="B2" value="340"/>
                    <measurement group_id="B3" value="347"/>
                    <measurement group_id="B4" value="1047"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lupus Quality of Life (lupus QOL) Domain Score</title>
          <description>The LupusQoL is a disease-specific, 34-item, self-report questionnaire designed to measure the health-related quality of life (HRQoL) of participants with SLE within 8 domains.Responses are based on a 5-point Likert scale where 0 (all of the time) to 4 (never). A LupusQoL score for each domain is reported on a 0 to 100 scale, with greater values indicating better HRQoL.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Physical Health</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.2" spread="24.98"/>
                    <measurement group_id="B2" value="59.1" spread="25.13"/>
                    <measurement group_id="B3" value="56.9" spread="26.17"/>
                    <measurement group_id="B4" value="58.4" spread="25.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emotional Health</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.7" spread="25.19"/>
                    <measurement group_id="B2" value="66.7" spread="23.99"/>
                    <measurement group_id="B3" value="64.6" spread="26.22"/>
                    <measurement group_id="B4" value="65.7" spread="25.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Body Image</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.1" spread="28.99"/>
                    <measurement group_id="B2" value="63.2" spread="27.67"/>
                    <measurement group_id="B3" value="61.9" spread="29.20"/>
                    <measurement group_id="B4" value="62.1" spread="28.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.1" spread="28.40"/>
                    <measurement group_id="B2" value="56.9" spread="26.75"/>
                    <measurement group_id="B3" value="53.6" spread="28.62"/>
                    <measurement group_id="B4" value="55.5" spread="27.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Planning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.2" spread="30.37"/>
                    <measurement group_id="B2" value="62.1" spread="28.69"/>
                    <measurement group_id="B3" value="59.0" spread="30.92"/>
                    <measurement group_id="B4" value="60.8" spread="30.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.0" spread="26.39"/>
                    <measurement group_id="B2" value="54.4" spread="25.54"/>
                    <measurement group_id="B3" value="53.4" spread="27.14"/>
                    <measurement group_id="B4" value="54.6" spread="26.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intimate Relationships</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.2" spread="33.92"/>
                    <measurement group_id="B2" value="63.3" spread="31.53"/>
                    <measurement group_id="B3" value="56.8" spread="34.21"/>
                    <measurement group_id="B4" value="58.8" spread="33.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Burden to Others</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.8" spread="30.70"/>
                    <measurement group_id="B2" value="51.9" spread="30.31"/>
                    <measurement group_id="B3" value="49.3" spread="32.39"/>
                    <measurement group_id="B4" value="51.3" spread="31.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Brief Fatigue Inventory (BFI) Score (Worst Level of Fatigue in the Last 24 Hours)</title>
          <description>BFI is a participants-reported scale that measures the severity of fatigue based on the worst fatigue experienced during the past 24-hours. The severity scores ranged from 0 (no fatigue) to 10 (fatigue as severe as you can imagine).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.8" spread="2.57"/>
                    <measurement group_id="B2" value="5.6" spread="2.81"/>
                    <measurement group_id="B3" value="5.6" spread="2.81"/>
                    <measurement group_id="B4" value="5.6" spread="2.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving an SLE Responder Index Response at Week 52</title>
        <description>Percentage of participants with a ≥ 5 point reduction from baseline in SELENA SLEDAI score, and no worsening (increase of &lt; 0.30 points from baseline) in PGA, and no new BILAG A organ domain score or 2 new BILAG B organ domain scores compared with baseline.
SELENA SLEDAI is calculated from 24 individual descriptors across 9 organ systems; 0 indicates inactive disease and the maximum theoretical score is 105; scores &gt; 20 are rare. PGA is a visual analog scale scored from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe). BILAG uses a single score for each of the 9 organ domains; range is from severe (A) to no disease (E). Participants who were unable to comply with allowed concomitant medications requirements were considered non-responders, as were participants who dropped out or were missing Week 52 data.</description>
        <time_frame>52 weeks</time_frame>
        <population>Intent to Treat population (ITT) all randomized participants who received at least 1 dose of study drug and evaluable SLE scores, excluding two sites' participants due to good clinical practice (GCP) issues.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2127399 Every 2 Weeks</title>
            <description>LY2127399: 120 mg administered via subcutaneous injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug.</description>
          </group>
          <group group_id="O2">
            <title>LY2127399 Every 4 Wks</title>
            <description>During the Treatment Period, for blinding purposes, patients will alternate injections of LY2127399 and injections of placebo every 2 weeks.
LY2127399: 120 mg administered via subcutaneous injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug.
Placebo every 4 weeks: Administered via subcutaneous injection for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo every 2 weeks: Administered via subcutaneous injection for 52 weeks. A matching loading dose will also be administered at the first dose</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving an SLE Responder Index Response at Week 52</title>
          <description>Percentage of participants with a ≥ 5 point reduction from baseline in SELENA SLEDAI score, and no worsening (increase of &lt; 0.30 points from baseline) in PGA, and no new BILAG A organ domain score or 2 new BILAG B organ domain scores compared with baseline.
SELENA SLEDAI is calculated from 24 individual descriptors across 9 organ systems; 0 indicates inactive disease and the maximum theoretical score is 105; scores &gt; 20 are rare. PGA is a visual analog scale scored from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe). BILAG uses a single score for each of the 9 organ domains; range is from severe (A) to no disease (E). Participants who were unable to comply with allowed concomitant medications requirements were considered non-responders, as were participants who dropped out or were missing Week 52 data.</description>
          <population>Intent to Treat population (ITT) all randomized participants who received at least 1 dose of study drug and evaluable SLE scores, excluding two sites' participants due to good clinical practice (GCP) issues.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="381"/>
                <count group_id="O2" value="378"/>
                <count group_id="O3" value="379"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.8"/>
                    <measurement group_id="O2" value="35.2"/>
                    <measurement group_id="O3" value="29.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Participants Able to Decrease Dose of Prednisone or Equivalent With No Increase in Disease Activity at Week 52</title>
        <description>A participant achieves corticosteroid sparing effects (quiescent disease) if they have met the following criteria during Weeks 24 through 52; able to decrease their dose of prednisone or equivalent to 7.5 mg/day or less, have quiescent disease (BILAG C score or better in all nine systems), and no BILAG A or B flares in the previous three months, without an increase in either antimalarials or immunosuppressants on or prior to the visit. Only participants receiving a prednisone or equivalent dose of more than 7.5 mg/day at baseline are included.</description>
        <time_frame>52 weeks</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug, a baseline use of prednisone or equivalent &gt;7.5 mg/day, excluding two sites' participants due to good clinical practice (GCP) issues.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2127399 Every 2 Weeks</title>
            <description>LY2127399: 120 mg administered via subcutaneous injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug.</description>
          </group>
          <group group_id="O2">
            <title>LY2127399 Every 4 Wks</title>
            <description>During the Treatment Period, for blinding purposes, patients will alternate injections of LY2127399 and injections of placebo every 2 weeks.
LY2127399: 120 mg administered via subcutaneous injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug.
Placebo every 4 weeks: Administered via subcutaneous injection for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo every 2 weeks: Administered via subcutaneous injection for 52 weeks. A matching loading dose will also be administered at the first dose</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Participants Able to Decrease Dose of Prednisone or Equivalent With No Increase in Disease Activity at Week 52</title>
          <description>A participant achieves corticosteroid sparing effects (quiescent disease) if they have met the following criteria during Weeks 24 through 52; able to decrease their dose of prednisone or equivalent to 7.5 mg/day or less, have quiescent disease (BILAG C score or better in all nine systems), and no BILAG A or B flares in the previous three months, without an increase in either antimalarials or immunosuppressants on or prior to the visit. Only participants receiving a prednisone or equivalent dose of more than 7.5 mg/day at baseline are included.</description>
          <population>All randomized participants who received at least 1 dose of study drug, a baseline use of prednisone or equivalent &gt;7.5 mg/day, excluding two sites' participants due to good clinical practice (GCP) issues.</population>
          <units>percentage of partipants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="197"/>
                <count group_id="O2" value="200"/>
                <count group_id="O3" value="196"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.5"/>
                    <measurement group_id="O2" value="17.0"/>
                    <measurement group_id="O3" value="16.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 52 Weeks in Anti-double Stranded Deoxyribonucleic Acid (Anti-dsDNA) Level</title>
        <description>Anti-double stranded deoxyribonucleic acid (anti-dsDNA) is a lab analyte used to assist in the diagnosis of SLE.</description>
        <time_frame>Baseline, 52 weeks</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug, excluding two sites' participants due to good clinical practice (GCP) issues and a non-missing result at Week 52.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2127399 Every 2 Weeks</title>
            <description>LY2127399: 120 mg administered via subcutaneous injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug.</description>
          </group>
          <group group_id="O2">
            <title>LY2127399 Every 4 Wks</title>
            <description>During the Treatment Period, for blinding purposes, patients will alternate injections of LY2127399 and injections of placebo every 2 weeks.
LY2127399: 120 mg administered via subcutaneous injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug.
Placebo every 4 weeks: Administered via subcutaneous injection for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo every 2 weeks: Administered via subcutaneous injection for 52 weeks. A matching loading dose will also be administered at the first dose</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 52 Weeks in Anti-double Stranded Deoxyribonucleic Acid (Anti-dsDNA) Level</title>
          <description>Anti-double stranded deoxyribonucleic acid (anti-dsDNA) is a lab analyte used to assist in the diagnosis of SLE.</description>
          <population>All randomized participants who received at least 1 dose of study drug, excluding two sites' participants due to good clinical practice (GCP) issues and a non-missing result at Week 52.</population>
          <units>international units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="381"/>
                <count group_id="O2" value="378"/>
                <count group_id="O3" value="377"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107.2" spread="113.50"/>
                    <measurement group_id="O2" value="110.4" spread="111.58"/>
                    <measurement group_id="O3" value="107.1" spread="112.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 52 Week Endpoint in Systemic Lupus Erythematosus Disease Activity Index (SLEDAI2K) Score</title>
        <description>SLE Disease Activity Index 2000 (SLEDAI-2K) score is a weighted, cumulative index of lupus disease activity. SLEDAI-2K is calculated from 24 individual descriptors across 9 organ systems; 0 indicates inactive disease and the maximum theoretical score is 105.</description>
        <time_frame>Baseline, 52 weeks</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug, excluding 2 sites' participants due to GCP issues and non-missing results; LOCF, defined as: endpoint is defined as the latest post-baseline response obtained on or prior to the date of Week 52 or the date of early discontinuation from the treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2127399 Every 2 Weeks</title>
            <description>LY2127399: 120 mg administered via subcutaneous injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug.</description>
          </group>
          <group group_id="O2">
            <title>LY2127399 Every 4 Wks</title>
            <description>During the Treatment Period, for blinding purposes, patients will alternate injections of LY2127399 and injections of placebo every 2 weeks.
LY2127399: 120 mg administered via subcutaneous injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug.
Placebo every 4 weeks: Administered via subcutaneous injection for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo every 2 weeks: Administered via subcutaneous injection for 52 weeks. A matching loading dose will also be administered at the first dose</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 52 Week Endpoint in Systemic Lupus Erythematosus Disease Activity Index (SLEDAI2K) Score</title>
          <description>SLE Disease Activity Index 2000 (SLEDAI-2K) score is a weighted, cumulative index of lupus disease activity. SLEDAI-2K is calculated from 24 individual descriptors across 9 organ systems; 0 indicates inactive disease and the maximum theoretical score is 105.</description>
          <population>All randomized participants who received at least 1 dose of study drug, excluding 2 sites' participants due to GCP issues and non-missing results; LOCF, defined as: endpoint is defined as the latest post-baseline response obtained on or prior to the date of Week 52 or the date of early discontinuation from the treatment period.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="377"/>
                <count group_id="O2" value="374"/>
                <count group_id="O3" value="376"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.7" spread="4.35"/>
                    <measurement group_id="O2" value="-4.9" spread="4.32"/>
                    <measurement group_id="O3" value="-4.6" spread="4.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Severe SLE Flare (SFI)</title>
        <description>The SFI uses the SELENA-SLEDAI disease activity index score, disease activity scenarios, treatment changes, and PGA to define mild/moderate and severe flares. The index takes into account the absolute change in total scores, new or worsening symptoms, and increases in corticosteroid use or hospitalization due to the disease activity.
Time to first severe SLE flare (SFI) (in days) is calculated as: (Start date of first severe SLE flare (SFI) - Date of randomization + 1).</description>
        <time_frame>Baseline through 52 weeks</time_frame>
        <population>Zero participants analyzed. Time to first severe SLE flare data was not collected for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2127399 Every 2 Weeks</title>
            <description>LY2127399: 120 mg administered via subcutaneous injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug.</description>
          </group>
          <group group_id="O2">
            <title>LY2127399 Every 4 Wks</title>
            <description>During the Treatment Period, for blinding purposes, patients will alternate injections of LY2127399 and injections of placebo every 2 weeks.
LY2127399: 120 mg administered via subcutaneous injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug.
Placebo every 4 weeks: Administered via subcutaneous injection for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo every 2 weeks: Administered via subcutaneous injection for 52 weeks. A matching loading dose will also be administered at first dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Severe SLE Flare (SFI)</title>
          <description>The SFI uses the SELENA-SLEDAI disease activity index score, disease activity scenarios, treatment changes, and PGA to define mild/moderate and severe flares. The index takes into account the absolute change in total scores, new or worsening symptoms, and increases in corticosteroid use or hospitalization due to the disease activity.
Time to first severe SLE flare (SFI) (in days) is calculated as: (Start date of first severe SLE flare (SFI) - Date of randomization + 1).</description>
          <population>Zero participants analyzed. Time to first severe SLE flare data was not collected for analysis.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With No Worsening in Physician Global Assessment (PGA) Score at 52 Weeks</title>
        <description>Physician's Global Assessment (PGA) is a single-item clinician rated assessment of the patient's current level of disease activity measured on a continuous 100 millimeter (mm) visual analytic scale with benchmarks of 0, 1, 2, and 3 from left to right corresponding to no, mild, moderate, and severe SLE disease activity. Scores are presented from 0 to 100. No worsening is defined as increase of ≥0.3 points.</description>
        <time_frame>52 weeks</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug, excluding two sites' participants due to good clinical practice (GCP) issues</population>
        <group_list>
          <group group_id="O1">
            <title>LY2127399 Every 2 Weeks</title>
            <description>LY2127399: 120 mg administered via subcutaneous injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug.</description>
          </group>
          <group group_id="O2">
            <title>LY2127399 Every 4 Wks</title>
            <description>During the Treatment Period, for blinding purposes, patients will alternate injections of LY2127399 and injections of placebo every 2 weeks.
LY2127399: 120 mg administered via subcutaneous injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug.
Placebo every 4 weeks: Administered via subcutaneous injection for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo every 2 weeks: Administered via subcutaneous injection for 52 weeks. A matching loading dose will also be administered at the first dose</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With No Worsening in Physician Global Assessment (PGA) Score at 52 Weeks</title>
          <description>Physician's Global Assessment (PGA) is a single-item clinician rated assessment of the patient's current level of disease activity measured on a continuous 100 millimeter (mm) visual analytic scale with benchmarks of 0, 1, 2, and 3 from left to right corresponding to no, mild, moderate, and severe SLE disease activity. Scores are presented from 0 to 100. No worsening is defined as increase of ≥0.3 points.</description>
          <population>All randomized participants who received at least 1 dose of study drug, excluding two sites' participants due to good clinical practice (GCP) issues</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="381"/>
                <count group_id="O2" value="378"/>
                <count group_id="O3" value="379"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.3"/>
                    <measurement group_id="O2" value="61.4"/>
                    <measurement group_id="O3" value="58.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 52 Week Endpoint in Brief Fatigue Inventory (BFI) Scores</title>
        <description>A participants-reported scale that measures the severity of fatigue based on the worst fatigue experienced during the past 24-hours. The severity scores ranged from 0 (no fatigue) to 10 (fatigue as severe as you can imagine).</description>
        <time_frame>Baseline, 52 weeks</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug, excluding 2 sites' participants due to GCP issues and non-missing results; LOCF, defined as: endpoint is defined as the latest post-baseline response obtained on or prior to the date of Week 52 or the date of early discontinuation from the treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2127399 Every 2 Weeks</title>
            <description>LY2127399: 120 mg administered via subcutaneous injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug.</description>
          </group>
          <group group_id="O2">
            <title>LY2127399 Every 4 Wks</title>
            <description>During the Treatment Period, for blinding purposes, patients will alternate injections of LY2127399 and injections of placebo every 2 weeks.
LY2127399: 120 mg administered via subcutaneous injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug.
Placebo every 4 weeks: Administered via subcutaneous injection for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo every 2 weeks: Administered via subcutaneous injection for 52 weeks. A matching loading dose will also be administered at the first dose</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 52 Week Endpoint in Brief Fatigue Inventory (BFI) Scores</title>
          <description>A participants-reported scale that measures the severity of fatigue based on the worst fatigue experienced during the past 24-hours. The severity scores ranged from 0 (no fatigue) to 10 (fatigue as severe as you can imagine).</description>
          <population>All randomized participants who received at least 1 dose of study drug, excluding 2 sites' participants due to GCP issues and non-missing results; LOCF, defined as: endpoint is defined as the latest post-baseline response obtained on or prior to the date of Week 52 or the date of early discontinuation from the treatment period.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="362"/>
                <count group_id="O2" value="363"/>
                <count group_id="O3" value="361"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="3.09"/>
                    <measurement group_id="O2" value="-0.9" spread="3.14"/>
                    <measurement group_id="O3" value="-0.6" spread="2.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 52 Week Endpoint Lupus Quality of Life (LupusQoL) Domain Scores</title>
        <description>The LupusQoL is a disease-specific, 34-item, self-report questionnaire designed to measure the health-related quality of life (HRQoL) of participants with SLE within 8 domains.Responses are based on a 5-point Likert scale where 0 (all of the time) to 4 (never). A LupusQoL score for each domain is reported on a 0 to 100 scale, with greater values indicating better HRQoL.</description>
        <time_frame>Baseline, 52 weeks</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug, excluding 2 sites' participants due to GCP issues and a non-missing result.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2127399 Every 2 Weeks</title>
            <description>LY2127399: 120 mg administered via subcutaneous injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug.</description>
          </group>
          <group group_id="O2">
            <title>LY2127399 Every 4 Wks</title>
            <description>During the Treatment Period, for blinding purposes, patients will alternate injections of LY2127399 and injections of placebo every 2 weeks.
LY2127399: 120 mg administered via subcutaneous injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug.
Placebo every 4 weeks: Administered via subcutaneous injection for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo every 2 weeks: Administered via subcutaneous injection for 52 weeks. A matching loading dose will also be administered at the first dose</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 52 Week Endpoint Lupus Quality of Life (LupusQoL) Domain Scores</title>
          <description>The LupusQoL is a disease-specific, 34-item, self-report questionnaire designed to measure the health-related quality of life (HRQoL) of participants with SLE within 8 domains.Responses are based on a 5-point Likert scale where 0 (all of the time) to 4 (never). A LupusQoL score for each domain is reported on a 0 to 100 scale, with greater values indicating better HRQoL.</description>
          <population>All randomized participants who received at least 1 dose of study drug, excluding 2 sites' participants due to GCP issues and a non-missing result.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="381"/>
                <count group_id="O2" value="378"/>
                <count group_id="O3" value="361"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Physical Health</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="121"/>
                    <count group_id="O2" value="133"/>
                    <count group_id="O3" value="111"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.7" spread="26.05"/>
                    <measurement group_id="O2" value="72.8" spread="24.53"/>
                    <measurement group_id="O3" value="72.8" spread="23.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emotional Health</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="121"/>
                    <count group_id="O2" value="133"/>
                    <count group_id="O3" value="111"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.2" spread="25.50"/>
                    <measurement group_id="O2" value="72.4" spread="24.08"/>
                    <measurement group_id="O3" value="73.1" spread="25.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Body Language</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="117"/>
                    <count group_id="O2" value="131"/>
                    <count group_id="O3" value="108"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.1" spread="26.21"/>
                    <measurement group_id="O2" value="75.0" spread="24.82"/>
                    <measurement group_id="O3" value="71.9" spread="28.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="121"/>
                    <count group_id="O2" value="133"/>
                    <count group_id="O3" value="111"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.0" spread="27.42"/>
                    <measurement group_id="O2" value="74.1" spread="24.94"/>
                    <measurement group_id="O3" value="73.2" spread="27.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Planning</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="121"/>
                    <count group_id="O2" value="133"/>
                    <count group_id="O3" value="111"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.3" spread="26.53"/>
                    <measurement group_id="O2" value="75.0" spread="29.07"/>
                    <measurement group_id="O3" value="74.5" spread="28.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="121"/>
                    <count group_id="O2" value="133"/>
                    <count group_id="O3" value="111"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.4" spread="25.51"/>
                    <measurement group_id="O2" value="68.8" spread="26.34"/>
                    <measurement group_id="O3" value="64.5" spread="24.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intimate Relationships</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="100"/>
                    <count group_id="O2" value="124"/>
                    <count group_id="O3" value="101"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.4" spread="29.01"/>
                    <measurement group_id="O2" value="68.8" spread="34.06"/>
                    <measurement group_id="O3" value="68.7" spread="30.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Burden to Others</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="121"/>
                    <count group_id="O2" value="133"/>
                    <count group_id="O3" value="111"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.7" spread="30.43"/>
                    <measurement group_id="O2" value="63.5" spread="30.34"/>
                    <measurement group_id="O3" value="63.7" spread="30.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First New British Isles Lupus Assessment Group (BILAG A) or 2 New BILAG B SLE Flares</title>
        <description>The British Isles Lupus Assessment Group (BILAG) instrument assesses global disease activity across 9 organ system domains. BILAG flare is assessed for each of the 9 organ domains using BILAG2004 index flare rules; A is a severe flare and B is a moderate flare.
Time to first BILAG A or two BILAG B flares (in days) is calculated as: (Start date of first BILAG A or two BILAG B flares - Date of randomization + 1). The two BILAG B flares must occur in different domains at the same visit.</description>
        <time_frame>Baseline through 52 weeks</time_frame>
        <population>Zero participants analyzed. Time first new British Isles Lupus Assessment Group (BILAG A) or 2 new BILAG B SLE flares data was not collected for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2127399 Every 2 Weeks</title>
            <description>LY2127399: 120 mg administered via subcutaneous injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug.</description>
          </group>
          <group group_id="O2">
            <title>LY2127399 Every 4 Wks</title>
            <description>During the Treatment Period, for blinding purposes, patients will alternate injections of LY2127399 and injections of placebo every 2 weeks.
LY2127399: 120 mg administered via subcutaneous injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug.
Placebo every 4 weeks: Administered via subcutaneous injection for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo every 2 weeks: Administered via subcutaneous injection for 52 weeks. A matching loading dose will also be administered at the first dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First New British Isles Lupus Assessment Group (BILAG A) or 2 New BILAG B SLE Flares</title>
          <description>The British Isles Lupus Assessment Group (BILAG) instrument assesses global disease activity across 9 organ system domains. BILAG flare is assessed for each of the 9 organ domains using BILAG2004 index flare rules; A is a severe flare and B is a moderate flare.
Time to first BILAG A or two BILAG B flares (in days) is calculated as: (Start date of first BILAG A or two BILAG B flares - Date of randomization + 1). The two BILAG B flares must occur in different domains at the same visit.</description>
          <population>Zero participants analyzed. Time first new British Isles Lupus Assessment Group (BILAG A) or 2 new BILAG B SLE flares data was not collected for analysis.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 52 Week Endpoint in PGA</title>
        <description>Physician's Global Assessment (PGA) is a single-item clinician rated assessment of the patient's current level of disease activity measured on a continuous 100-mm visual analytic scale with benchmarks of 0, 1, 2, and 3 from left to right corresponding to no, mild, moderate, and severe SLE disease activity. Scores range from 0, being worst possible to 100 being very active or best possible.</description>
        <time_frame>Baseline, 52 weeks</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug, excluding 2 sites' participants due to GCP issues and non-missing results; LOCF, defined as: endpoint is defined as the latest post-baseline response obtained on or prior to the date of Week 52 or the date of early discontinuation from the treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2127399 Every 2 Weeks</title>
            <description>LY2127399: 120 mg administered via subcutaneous injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug.</description>
          </group>
          <group group_id="O2">
            <title>LY2127399 Every 4 Wks</title>
            <description>During the Treatment Period, for blinding purposes, patients will alternate injections of LY2127399 and injections of placebo every 2 weeks.
LY2127399: 120 mg administered via subcutaneous injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug.
Placebo every 4 weeks: Administered via subcutaneous injection for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo every 2 weeks: Administered via subcutaneous injection for 52 weeks. A matching loading dose will also be administered at the first dose</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 52 Week Endpoint in PGA</title>
          <description>Physician's Global Assessment (PGA) is a single-item clinician rated assessment of the patient's current level of disease activity measured on a continuous 100-mm visual analytic scale with benchmarks of 0, 1, 2, and 3 from left to right corresponding to no, mild, moderate, and severe SLE disease activity. Scores range from 0, being worst possible to 100 being very active or best possible.</description>
          <population>All randomized participants who received at least 1 dose of study drug, excluding 2 sites' participants due to GCP issues and non-missing results; LOCF, defined as: endpoint is defined as the latest post-baseline response obtained on or prior to the date of Week 52 or the date of early discontinuation from the treatment period.</population>
          <units>millimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="375"/>
                <count group_id="O2" value="374"/>
                <count group_id="O3" value="375"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.8" spread="21.97"/>
                    <measurement group_id="O2" value="-20.8" spread="22.33"/>
                    <measurement group_id="O3" value="-20.2" spread="22.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With an Increase in Corticosteroids Dose at 52 Weeks</title>
        <description>An increase in corticosteroids at a visit was defined as a change from baseline greater than 2.5 mg/day in dose or prednisone or equivalent using average daily dose of corticosteroids taken since the previous scheduled visit.</description>
        <time_frame>52 weeks</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug, excluding two sites' participants due to good clinical practice (GCP) issues.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2127399 Every 2 Weeks</title>
            <description>LY2127399: 120 mg administered via subcutaneous injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug.</description>
          </group>
          <group group_id="O2">
            <title>LY2127399 Every 4 Wks</title>
            <description>During the Treatment Period, for blinding purposes, patients will alternate injections of LY2127399 and injections of placebo every 2 weeks.
LY2127399: 120 mg administered via subcutaneous injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug.
Placebo every 4 weeks: Administered via subcutaneous injection for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo every 2 weeks: Administered via subcutaneous injection for 52 weeks. A matching loading dose will also be administered at the first dose</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an Increase in Corticosteroids Dose at 52 Weeks</title>
          <description>An increase in corticosteroids at a visit was defined as a change from baseline greater than 2.5 mg/day in dose or prednisone or equivalent using average daily dose of corticosteroids taken since the previous scheduled visit.</description>
          <population>All randomized participants who received at least 1 dose of study drug, excluding two sites' participants due to good clinical practice (GCP) issues.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="381"/>
                <count group_id="O2" value="378"/>
                <count group_id="O3" value="379"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7"/>
                    <measurement group_id="O2" value="9.1"/>
                    <measurement group_id="O3" value="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 52 Weeks Endpoint in SELENA-SLEDAI Disease Activity Score</title>
        <description>Safety of Estrogens in Lupus Erythematosus National Assessment - SLE Disease Activity Index (SELENA-SLEDAI) score is a weighted, cumulative index of lupus disease activity. SELENA-SLEDAI is calculated from 24 individual descriptors across 9 organ systems; 0 indicates inactive disease and the maximum theoretical score is 105.</description>
        <time_frame>Baseline, 52 weeks</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug, excluding 2 sites' participants due to GCP issues and non-missing results; LOCF, defined as: endpoint is defined as the latest post-baseline response obtained on or prior to the date of Week 52 or the date of early discontinuation from the treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2127399 Every 2 Weeks</title>
            <description>LY2127399: 120 mg administered via subcutaneous injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug.</description>
          </group>
          <group group_id="O2">
            <title>LY2127399 Every 4 Wks</title>
            <description>During the Treatment Period, for blinding purposes, patients will alternate injections of LY2127399 and injections of placebo every 2 weeks.
LY2127399: 120 mg administered via subcutaneous injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug.
Placebo every 4 weeks: Administered via subcutaneous injection for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo every 2 weeks: Administered via subcutaneous injection for 52 weeks. A matching loading dose will also be administered at the first dose</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 52 Weeks Endpoint in SELENA-SLEDAI Disease Activity Score</title>
          <description>Safety of Estrogens in Lupus Erythematosus National Assessment - SLE Disease Activity Index (SELENA-SLEDAI) score is a weighted, cumulative index of lupus disease activity. SELENA-SLEDAI is calculated from 24 individual descriptors across 9 organ systems; 0 indicates inactive disease and the maximum theoretical score is 105.</description>
          <population>All randomized participants who received at least 1 dose of study drug, excluding 2 sites' participants due to GCP issues and non-missing results; LOCF, defined as: endpoint is defined as the latest post-baseline response obtained on or prior to the date of Week 52 or the date of early discontinuation from the treatment period.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="381"/>
                <count group_id="O2" value="378"/>
                <count group_id="O3" value="376"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.6" spread="4.19"/>
                    <measurement group_id="O2" value="-4.7" spread="4.11"/>
                    <measurement group_id="O3" value="-4.8" spread="4.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving a Response as Measured by Modified SRI With No BILAG A or No More Than 1 BILAG B Organ Domain Flares at 52 Weeks</title>
        <description>Percentage of participants with a ≥ 5 point reduction from baseline in SELENA SLEDAI score, and no worsening (increase of &lt; 0.30 points from baseline) in PGA, and no new BILAG A or no more than 1 new BILAG B organ domain flare compared with baseline. (Primary outcome modified to use BILAG flare instead of BILAG disease score)
SELENA SLEDAI is calculated from 24 individual descriptors across 9 organ systems; 0 indicates inactive disease and the maximum theoretical score is 105. PGA is a visual analog scale scored from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe). BILAG flare is assessed for each of the 9 organ domains; A is a severe flare and B is a moderate flare. Patients who were unable to comply with allowed concomitant medications requirements were considered non-responders, as were participants who dropped out or were missing Week 52 data.</description>
        <time_frame>52 weeks</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug, excluding two sites' participants due to good clinical practice (GCP) issues.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2127399 Every 2 Weeks</title>
            <description>LY2127399: 120 mg administered via subcutaneous injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug.</description>
          </group>
          <group group_id="O2">
            <title>LY2127399 Every 4 Wks</title>
            <description>During the Treatment Period, for blinding purposes, patients will alternate injections of LY2127399 and injections of placebo every 2 weeks.
LY2127399: 120 mg administered via subcutaneous injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug.
Placebo every 4 weeks: Administered via subcutaneous injection for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo every 2 weeks: Administered via subcutaneous injection for 52 weeks. A matching loading dose will also be administered at the first dose</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving a Response as Measured by Modified SRI With No BILAG A or No More Than 1 BILAG B Organ Domain Flares at 52 Weeks</title>
          <description>Percentage of participants with a ≥ 5 point reduction from baseline in SELENA SLEDAI score, and no worsening (increase of &lt; 0.30 points from baseline) in PGA, and no new BILAG A or no more than 1 new BILAG B organ domain flare compared with baseline. (Primary outcome modified to use BILAG flare instead of BILAG disease score)
SELENA SLEDAI is calculated from 24 individual descriptors across 9 organ systems; 0 indicates inactive disease and the maximum theoretical score is 105. PGA is a visual analog scale scored from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe). BILAG flare is assessed for each of the 9 organ domains; A is a severe flare and B is a moderate flare. Patients who were unable to comply with allowed concomitant medications requirements were considered non-responders, as were participants who dropped out or were missing Week 52 data.</description>
          <population>All randomized participants who received at least 1 dose of study drug, excluding two sites' participants due to good clinical practice (GCP) issues.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="381"/>
                <count group_id="O2" value="378"/>
                <count group_id="O3" value="379"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Responder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.8"/>
                    <measurement group_id="O2" value="35.2"/>
                    <measurement group_id="O3" value="29.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Responder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.2"/>
                    <measurement group_id="O2" value="64.8"/>
                    <measurement group_id="O3" value="70.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With No New BILAG A and No More Than One New BILAG B Disease Activity Scores Compared to Baseline</title>
        <description>The BILAG2004 index is a validated global disease activity index designed on the basis of the physician's ITT, focusing on changes in disease manifestations (new, improved, worsening, etc) occurring in the last 4 weeks compared with the previous 4 weeks.
The instrument assesses 97 clinical signs, symptoms, and laboratory parameters across 9 organ system domains: constitutional, mucocutaneous, neuropsychiatric, musculoskeletal, cardiorespiratory, gastrointestinal, opthalmic, renal and hematology.</description>
        <time_frame>Baseline through 52 weeks</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug, excluding two sites' participants due to good clinical practice (GCP) issues.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2127399 Every 2 Weeks</title>
            <description>LY2127399: 120 mg administered via subcutaneous injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug.</description>
          </group>
          <group group_id="O2">
            <title>LY2127399 Every 4 Wks</title>
            <description>During the Treatment Period, for blinding purposes, patients will alternate injections of LY2127399 and injections of placebo every 2 weeks.
LY2127399: 120 mg administered via subcutaneous injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug.
Placebo every 4 weeks: Administered via subcutaneous injection for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo every 2 weeks: Administered via subcutaneous injection for 52 weeks. A matching loading dose will also be administered at the first dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With No New BILAG A and No More Than One New BILAG B Disease Activity Scores Compared to Baseline</title>
          <description>The BILAG2004 index is a validated global disease activity index designed on the basis of the physician's ITT, focusing on changes in disease manifestations (new, improved, worsening, etc) occurring in the last 4 weeks compared with the previous 4 weeks.
The instrument assesses 97 clinical signs, symptoms, and laboratory parameters across 9 organ system domains: constitutional, mucocutaneous, neuropsychiatric, musculoskeletal, cardiorespiratory, gastrointestinal, opthalmic, renal and hematology.</description>
          <population>All randomized participants who received at least 1 dose of study drug, excluding two sites' participants due to good clinical practice (GCP) issues.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="381"/>
                <count group_id="O2" value="378"/>
                <count group_id="O3" value="379"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="247"/>
                    <measurement group_id="O2" value="234"/>
                    <measurement group_id="O3" value="219"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>All participants who received at least 1 dose of study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>LY2127399 Every 2 Weeks</title>
          <description>LY2127399: 120 mg administered via subcutaneous injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug.</description>
        </group>
        <group group_id="E2">
          <title>LY2127399 Every 4 Wks</title>
          <description>During the Treatment Period, for blinding purposes, patients will alternate injections of LY2127399 and injections of placebo every 2 weeks.
LY2127399: 120 mg administered via subcutaneous injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug.
Placebo every 4 weeks: Administered via subcutaneous injection for 52 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo every 2 weeks: Administered via subcutaneous injection for 52 weeks. A matching loading dose will also be administered at the first dose</description>
        </group>
        <group group_id="E4">
          <title>LY2127399 Every 2 Weeks, Follow Up</title>
          <description>24-48 weeks post last dose</description>
        </group>
        <group group_id="E5">
          <title>LY2127399 Every 4 Wks, Follow Up</title>
          <description>24-48 weeks post last dose</description>
        </group>
        <group group_id="E6">
          <title>Placebo, Follow Up</title>
          <description>24-48 weeks post last dose</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="389"/>
                <counts group_id="E3" subjects_affected="50" subjects_at_risk="387"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="103"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="105"/>
                <counts group_id="E6" subjects_affected="23" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Antiphospholipid syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Autoimmune haemolytic anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Haemorrhagic anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Histiocytosis haematophagic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Thrombocytosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Lupus endocarditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Mitral valve prolapse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Myocarditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Sickle cell anaemia with crisis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="386"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Gastritis atrophic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Gastrointestinal inflammation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Obstruction gastric</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Rectal ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Varices oesophageal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Vasculitis gastrointestinal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Generalised oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Hepatic steatosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Type III immune complex mediated reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="386"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="389"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Disseminated tuberculosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Gastroenteritis norovirus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Haematoma infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Infected skin ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Klebsiella bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Mycobacterial infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Pancreas infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Parotitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Pharyngotonsillitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="386"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="389"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="105"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Salpingo-oophoritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Sinusitis bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Staphylococcal skin infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Superinfection bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="386"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="386"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="389"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Compression fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Medication error</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Cervical spinal stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Polyarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>SLE arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Systemic lupus erythematosus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="386"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="389"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="387"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="103"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E6" events="3" subjects_affected="2" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Tendon disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Brenner tumour</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Haemangioma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Intestinal adenocarcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Central nervous system inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Cerebral venous thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Neuropsychiatric lupus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Radiculopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Vasculitis cerebral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Vertebrobasilar insufficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Pre-eclampsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Affect lability</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Affective disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Generalised anxiety disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Mental disorder due to a general medical condition</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Glomerulonephritis proliferative</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Lupus cystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Lupus nephritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="386"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="387"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="7" subjects_affected="7" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Mesangioproliferative glomerulonephritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Nephrotic syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Adenomyosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Ovarian cyst ruptured</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cutaneous lupus erythematosus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Erythema multiforme</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Hypersensitivity vasculitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Systemic lupus erythematosus rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Female sterilisation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Femoral artery occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="250" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="243" subjects_at_risk="389"/>
                <counts group_id="E3" subjects_affected="246" subjects_at_risk="387"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="103"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="105"/>
                <counts group_id="E6" subjects_affected="13" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="386"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="389"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="386"/>
                <counts group_id="E2" events="14" subjects_affected="12" subjects_at_risk="389"/>
                <counts group_id="E3" events="12" subjects_affected="12" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="386"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="389"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="386"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="389"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="26" subjects_affected="22" subjects_at_risk="386"/>
                <counts group_id="E2" events="33" subjects_affected="29" subjects_at_risk="389"/>
                <counts group_id="E3" events="30" subjects_affected="23" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="386"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="389"/>
                <counts group_id="E3" events="17" subjects_affected="10" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="386"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="389"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="386"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="389"/>
                <counts group_id="E3" events="9" subjects_affected="7" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="19" subjects_affected="17" subjects_at_risk="386"/>
                <counts group_id="E2" events="42" subjects_affected="31" subjects_at_risk="389"/>
                <counts group_id="E3" events="24" subjects_affected="21" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="19" subjects_affected="16" subjects_at_risk="386"/>
                <counts group_id="E2" events="17" subjects_affected="14" subjects_at_risk="389"/>
                <counts group_id="E3" events="12" subjects_affected="11" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="386"/>
                <counts group_id="E2" events="16" subjects_affected="15" subjects_at_risk="389"/>
                <counts group_id="E3" events="11" subjects_affected="10" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="17" subjects_affected="11" subjects_at_risk="386"/>
                <counts group_id="E2" events="10" subjects_affected="7" subjects_at_risk="389"/>
                <counts group_id="E3" events="8" subjects_affected="6" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="386"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="389"/>
                <counts group_id="E3" events="11" subjects_affected="10" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="386"/>
                <counts group_id="E2" events="14" subjects_affected="10" subjects_at_risk="389"/>
                <counts group_id="E3" events="16" subjects_affected="8" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="18" subjects_affected="15" subjects_at_risk="386"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="389"/>
                <counts group_id="E3" events="19" subjects_affected="17" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="386"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="389"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="386"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="389"/>
                <counts group_id="E3" events="10" subjects_affected="9" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="386"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="389"/>
                <counts group_id="E3" events="12" subjects_affected="11" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="386"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="389"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="105"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="386"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="389"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="46" subjects_affected="29" subjects_at_risk="386"/>
                <counts group_id="E2" events="35" subjects_affected="33" subjects_at_risk="389"/>
                <counts group_id="E3" events="48" subjects_affected="37" subjects_at_risk="387"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="386"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="389"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="17" subjects_affected="13" subjects_at_risk="386"/>
                <counts group_id="E2" events="19" subjects_affected="18" subjects_at_risk="389"/>
                <counts group_id="E3" events="18" subjects_affected="14" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="22" subjects_affected="16" subjects_at_risk="386"/>
                <counts group_id="E2" events="16" subjects_affected="15" subjects_at_risk="389"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="86" subjects_affected="55" subjects_at_risk="386"/>
                <counts group_id="E2" events="55" subjects_affected="41" subjects_at_risk="389"/>
                <counts group_id="E3" events="72" subjects_affected="51" subjects_at_risk="387"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="105"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="100" subjects_affected="68" subjects_at_risk="386"/>
                <counts group_id="E2" events="76" subjects_affected="52" subjects_at_risk="389"/>
                <counts group_id="E3" events="77" subjects_affected="51" subjects_at_risk="387"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="103"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="105"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Vulvovaginal mycotic infection</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="386"/>
                <counts group_id="E2" events="12" subjects_affected="9" subjects_at_risk="389"/>
                <counts group_id="E3" events="11" subjects_affected="8" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="386"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="389"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="386"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="386"/>
                <counts group_id="E2" events="17" subjects_affected="15" subjects_at_risk="389"/>
                <counts group_id="E3" events="14" subjects_affected="11" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="386"/>
                <counts group_id="E2" events="30" subjects_affected="28" subjects_at_risk="389"/>
                <counts group_id="E3" events="24" subjects_affected="19" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="386"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="389"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="386"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="389"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="389"/>
                <counts group_id="E3" events="12" subjects_affected="10" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="386"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="389"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="386"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="389"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="386"/>
                <counts group_id="E2" events="31" subjects_affected="19" subjects_at_risk="389"/>
                <counts group_id="E3" events="15" subjects_affected="15" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="48" subjects_affected="34" subjects_at_risk="386"/>
                <counts group_id="E2" events="56" subjects_affected="35" subjects_at_risk="389"/>
                <counts group_id="E3" events="54" subjects_affected="45" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="105"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="386"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="389"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="386"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="389"/>
                <counts group_id="E3" events="12" subjects_affected="12" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="386"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="389"/>
                <counts group_id="E3" events="17" subjects_affected="16" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="386"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="389"/>
                <counts group_id="E3" events="18" subjects_affected="18" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="386"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="389"/>
                <counts group_id="E3" events="11" subjects_affected="10" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="386"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="389"/>
                <counts group_id="E3" events="21" subjects_affected="20" subjects_at_risk="387"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Due to product program termination, not all analyses were completed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

